![]() ![]() Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. The following information should be read in conjunction with the financial statements and management's discussion and analysis, which are available under Novamind's SEDAR profile at About Novamind The following table presents selected financial information from Novamind's reviewed condensed interim financial statements for the three and nine months ended March 31 st, 2021. Total working capital of $9,984,071 to fund operations.Debt-free balance sheet with $7,616,948 in cash and $2,355,988 in marketable securities.Total revenue of $1,846,132, +43% quarter-over-quarter, driven by increased patient volume at the Company's four operating clinics.Novamind will continue to execute on its aggressive growth initiatives in 2021, further expanding organically and through acquisitions ahead of the FDA's anticipated approvals of MDMA and psilocybin." "The contract with Merck to research a promising new drug, leveraged our expertise in patient recruitment and patient management. ![]() "Since listing on the CSE this January, Novamind has demonstrated its ability to rapidly scale access to innovative mental health treatment and psychedelic medicine," said Yaron Conforti, CEO and Director, Novamind.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |